FAST 2018 Fall Closing Showcase Celebrates Seven Companies | Read More
Meet with Representatives of JT Pharma | Read More
CLSI and the Canadian Technology Accelerator Program Partner in assisting Emerging Canadian Life Science Companies | Read More
FAST grad (Fall 2017) Pheronym is named winner of the Sacramento Region Innovation Award in Food and Agribusiness | Read MoreWatch video presentation here
Watch FAST grad (Fall 2017) Inflammatix’s TED Talk on Immune Profiling: A New Way to Diagnose Infections | Watch Here
FAST grad (Spring 2017) HepaTx’s President and CEO, Eric Schuur discusses how HepaTx came about and how his work will benefit people with liver disease |Read More
FAST grad (Spring 2016) Eidos Therapeutics announced the FDA has granted orphan drug designation for AG10, for the treatment of transthyretin amyloidosis | Read More
FAST grad (Spring 2016) Paragon Genomics announced introduction of CleanPlex® UMI Lung Cancer Panel, which can detect highly accurate low-frequency variants and mutations for liquid biopsies. The company also announced they have entered a partnership with SOPHiA GENETICS , a leader in Data-Driven Medicine to incorporate their CleanPlex® NGS target enrichment technologies into the SOPHiA AI Platform to be used in 850 hospitals in 72 countries | Read More
FAST grad (Spring 2015) Magnetic Insight announced they raised $18M Series A led by 5AM Ventures to support commercial growth of magnetic particle imaging in cell therapy, vascular and oncology | Read More
The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a twelve-week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.
JLABS: Meet with Bioverge, South San Francisco Register Here
CARB-X
CARB-X 2017-18 Annual Report: Progress Against Superbugs | Read Here
CARB-X calls for new ‘open science’ era in antibacterial innovation: Sharing scientific data will help speed the delivery of new antibiotics and other life-saving products to fight superbugs | Read More
Powered by CARB-X company,Summit Therapeutics discovered multiple new mechanism antibiotics to treat “superbug” pathogens using its Discuva platform | Read More
Powered by CARB-X company, Tetraphase Pharmaceuticals announced FDA approval of Xereva for complicated intra-abdominal infections | Read More
Powered by CARB-X company, MicuRxannounced receipt of FDA’s QIDP and Fast Track designations for contezolid for the treatment of acute bacterial skin and skin structure infections | Read More
Powered by CARB-X company, Vedanta Biosciences’ CEO Bernat Olle shares a recap of a recent FDA NIH workshop discussing the need for regulatory oversight for microbiome drug developers | Read More
Powered by CARB-X company, Spero Therapeuticswas granted Qualified Infectious Disease Product (QIDP) designation for SPR206, a product candidate for the treatment of complicated urinary tract infectious | Read More
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With more than $500 million to invest, CARB-X funds the best science from around the world. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent and treat life-threatening bacterial infections. CARB-X operates through Boston University. Other partners include RTI International, the Broad Institute of Harvard and MIT, MassBio, and the California Life Sciences Institute (CLSI). http://www.carb-x.org/
CLSI helps build the next generation of life science professionals by bringing industry and institutions of learning together to improve STEM education in California and to inspire and develop life science careers. CLSI also works to ensure that the current and anticipated talent needs of the industry are met, and that the workforce pipeline for the industry remains strong.
Upcoming Events
12/13-14
BioBasics: Biotech For The Non-Scientist, South San Francisco Register Here
1/25-26
UC San Diego Extension: MCLE – Technology Licensing Workshop, San Diego Register Here
2/4
CLSA: Leadership EDGE for Women, South San Francisco Register Here
2/11-15
UCSF Department of Bioengineering and Therapeutic Sciences: Pharmacokinetics for Pharmaceutical Scientists Course, South San Francisco Register Here
3/4
CLSA: Leadership EDGE for Women, South San Francisco Register Here
3/14
The ART of Inclusive Communication, San Diego Register Here
3/21-5/2
(Four Days) From Laboratory to Leadership – 25th Anniversary Edition, South San Francisco Register Here
4/1
Leadership EDGE for Women, South San Francisco Register Here
ABOUT CALIFORNIA LIFE SCIENCES INSTITUTE
California Life Sciences Institute (CLSI) supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem. Our mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI also serves as an accelerator for CARB-X, the world’s largest public-private partnership devoted to early stage antibacterial R&D.
CLSI is an affiliate of the California Life Sciences Association (CLSA), which represents California’s leading life sciences organizations. The California Life Sciences Institute is a non-profit 501(c)(3), and was established in 1990 as the BayBio Institute.
California Life Sciences Institute 685 Gateway Blvd., Suite 100 South San Francisco California 94080
You received this email because you are subscribed to Events from California Life Sciences .
Update your email preferences to choose the types of emails you receive.